M. E. Lebsack

619 citations
10 papers · 461 indexed · h-index 6

M. E. Lebsack

10 papers receiving 422 citations

Peers

M. E. Lebsack
Comparison fields: 5 of 70
  • Rheumatology 188
  • Hematology 105
  • Molecular Medicine 29
  • Pharmacology 93
  • Immunology 111
Replace David L. Hyslop with:
David L. Hyslop United States
José Luis Marenco Spain
Risa Tanaka Japan
Marina Mantzourani Greece
Yaowei Zhu United States
Kanako Kitahara Japan
Jinpiao Lin China
T J Constable United Kingdom
Mariana Díaz‐Almirón Spain
Shin Okuyama Japan
M. E. Lebsack relative to David L. Hyslop United States David L. Hyslop's profile →
Citations per field
00.5×12×
David L. Hyslop · 1×
Citations per year

Countries citing papers authored by M. E. Lebsack

Since Specialization
Citations

This map shows the geographic impact of M. E. Lebsack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. E. Lebsack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. E. Lebsack more than expected).

Fields of papers citing papers by M. E. Lebsack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. E. Lebsack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. E. Lebsack. The network helps show where M. E. Lebsack may publish in the future.

Co-authorship network

The 25 scholars most cited alongside M. E. Lebsack, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. E. Lebsack Line = papers co-authored together M. E. Lebsack links everyone, so they are left out of the graph.

All Works

10 of 10 papers shown
#Work
1 2000117
2
Safety of FLT3 ligand in healthy volunteers
199715
3 1996196
4 19969
5 19935
6 19922
7 199225
8 19912
9 198985
10 19885

About M. E. Lebsack

M. E. Lebsack is a scholar working on Molecular Medicine, Pharmacology, Pharmacology, Analytical Chemistry and Emergency Medicine, having authored 10 papers that have together received 461 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (4 papers), Poisoning and overdose treatments (2 papers), Antibiotic Resistance in Bacteria (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Analytical Methods in Pharmaceuticals (2 papers), Cancer therapeutics and mechanisms (1 paper), Acute Myeloid Leukemia Research (1 paper) and Neutropenia and Cancer Infections (1 paper). The work is most often cited by research in Rheumatology (188 citations), Hematology (105 citations), Molecular Medicine (29 citations), Pharmacology (93 citations) and Immunology (111 citations). M. E. Lebsack has collaborated with scholars based in United States and Canada. Frequent co-authors include Janice L. Lookabaugh, Gary V. Gordon, G. Campion, Abbe Rubin, Roberta Hanna, Joan Korth‐Bradley, Donna Simcoe, Allen J. Sedman, Jerome J. Schentag and Thaddeus H. Grasela. Their work appears in journals such as The Journal of Clinical Pharmacology, Antimicrobial Agents and Chemotherapy, Journal of Clinical Oncology, Annals of Pharmacotherapy and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026